naringenin has been researched along with Disease Exacerbation in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, C; Jiang, T; Liu, Z; Song, C; Wu, K; Xu, X; Yu, T; Zhang, L; Zhang, X | 1 |
| Dwivedi, A; Gupta, K; Kapoor, R; Sirohi, VK | 1 |
| Assini, JM; DiMattia, AS; Huff, MW; Khami, M; Koppes, JB; Mulvihill, EE; Sawyez, CG; Sutherland, BG; Whitman, SC | 1 |
3 other study(ies) available for naringenin and Disease Exacerbation
| Article | Year |
|---|---|
Topics: Antioxidants; Citrus; Disease Progression; Flavanones; Humans; Osteosarcoma | 2018 |
Naringenin ameliorates progression of endometriosis by modulating Nrf2/Keap1/HO1 axis and inducing apoptosis in rats.
Topics: Animals; Apoptosis; Biomarkers; Cell Line, Tumor; Cell Movement; Disease Progression; Endometriosis; Endometrium; Female; Flavanones; Heme Oxygenase (Decyclizing); Kelch-Like ECH-Associated Protein 1; Membrane Potential, Mitochondrial; Neoplasm Transplantation; NF-E2-Related Factor 2; Nitric Oxide; Rats; Reactive Oxygen Species; Signal Transduction; Tumor Necrosis Factor-alpha | 2019 |
Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice.
Topics: Animals; Aorta; Aortic Diseases; Atherosclerosis; Cholesterol; Diet, Atherogenic; Dietary Fats; Disease Models, Animal; Disease Progression; Fatty Liver; Flavanones; Hyperinsulinism; Hyperlipidemias; Hypolipidemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; Receptors, LDL; Time Factors; Triglycerides | 2010 |